MAPK/ERK pathway: Difference between revisions
No edit summary |
No edit summary |
||
Line 33: | Line 33: | ||
===MAPKs=== | ===MAPKs=== | ||
*[[Mitogen-activated protein kinase kinase]] | |||
*[[Mitogen-activated protein kinase]] | *[[Mitogen-activated protein kinase]] | ||
*[[Michael Roberts/BIOL115/ERK2]] | *[[Michael Roberts/BIOL115/ERK2]] | ||
*[[UMass Chem 423 Student Projects 2011-2#p38 kinase|p38 MAPK (UMass Chem 423 Student Projects 2011-2)]] | *[[UMass Chem 423 Student Projects 2011-2#p38 kinase|p38 MAPK (UMass Chem 423 Student Projects 2011-2)]] |
Revision as of 16:46, 17 February 2022
Under development!!! MAPK/ERK pathway (also known as the Ras-Raf-MEK-ERK pathway) is a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell. Cell surface receptors that can activate this pathway via GRB2Epidermal Growth Factor Receptor (EGFR; see also Epidermal growth factor). EGFR belongs to Receptor tyrosine kinases, class I. Trk A/B: High affinity nerve growth factor receptor (TrkA). TrkB tyrosine kinase receptor. See also Neurotrophin. Fibroblast growth factor receptor Platelet-derived growth factors and receptors Growth factor receptor-bound proteinsGrowth factor receptor-bound proteins (GRB) are adaptor proteins. GRBs contain SH2, Ras-associated (RA) and pleckstrin homology (PH) domains. For additional details on GRB10 see Grb10 SH2 Domain. Rho guanine nucleotide exchange factorRas activationAllosteric modulation of H-Ras GTPase. Kinase cascadeRAF kinaseB-Raf is related to retroviral oncogenes and participates in cellular signal transduction. B-Raf domains include the kinase domain - residues 444-721 and Ras-binding domain - residues 153-237. Mutated B-Raf was found in some human cancers[1]. See more in B-RAF with PLX4032. c-Raf is part of the MAPK pathway. c-Raf domains include the kinase domain - residues 323-618, cysteine-rich domain – residues 136-187 and Ras-binding domain - residues 51-132. Mutations of c-Raf are possible causes of Noonan syndrome[2]. For details on c-Raf see Molecular Playground/C-Raf. Mitogen-activated protein kinase kinase kinase MAPKs |
|
ReferencesReferences
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089